Liquidia CorpLQDA
About: Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
Employees: 170
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
79% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 38
63% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 19
24% more call options, than puts
Call options by funds: $17.1M | Put options by funds: $13.8M
19% more capital invested
Capital invested by funds: $526M [Q3] → $625M (+$98.6M) [Q4]
6% more funds holding
Funds holding: 154 [Q3] → 163 (+9) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 7 [Q3] → 7 (+0) [Q4]
2.44% less ownership
Funds ownership: 63.18% [Q3] → 60.74% (-2.44%) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Needham Serge Belanger 36% 1-year accuracy 44 / 123 met price target | 82%upside $25 | Buy Reiterated | 10 Apr 2025 |
Scotiabank Greg Harrison 24% 1-year accuracy 10 / 41 met price target | 148%upside $34 | Sector Outperform Maintained | 20 Mar 2025 |
HC Wainwright & Co. Andrew Fein 27% 1-year accuracy 95 / 352 met price target | 111%upside $29 | Buy Reiterated | 20 Mar 2025 |
Financial journalist opinion
Based on 3 articles about LQDA published over the past 30 days
